Alvotech
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALVO.IC | ALKS | NBIX | AMRX | BCRX | PCRX | |
|---|---|---|---|---|---|---|
| Market cap | 221.94B | 6.92B | 13.79B | 6.68B | 1.99B | 1.45B |
| P/E (TTM) | — | 108.5 | 19.9 | 39.1 | — | 103.8 |
| Forward P/E | — | 22.8 | 11.4 | 16.1 | 8.3 | 10.5 |
| Price/book | -1,158.3 | 3.8 | 3.7 | 186.2 | -4.4 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −41.05% | +33.05% | −3.98% | +87.30% | +12.41% | +57.86% |
| Today | +0.97% | +2.79% | −0.91% | −0.36% | −2.87% | +0.03% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ALVO.IC news ›Alvotech (NASDAQ:ALVO) Stock Has Consensus Price Target of $8.50
Posted by Michael Walen on Oct 18th, 2026 Get Our Latest Stock Report on ALVO Shares of Alvotech stock opened at $5.00 on Tuesday. Alvotech has a 12-month low of $2.94 and a 12-month high of $8.74. The firm has a market capitalization of…
Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)
Posted by Michael Walen on Oct 18th, 2026 Alvotech (NASDAQ:ALVO – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
BioPharm International Alvotech and Advanz Pharma announced October 14, 2026, the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in…
Alvotech files first known aflibercept 8 mg biosimilar with EMA
Ophthalmology Times Alvotech files first known aflibercept 8 mg biosimilar with EMA AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027. Alvotech and Advanz Pharma…
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Oct 14, 2026 4:30am EDT AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency…
Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program
Actinium Pharmaceuticals, Inc. has amended its Investigational New Drug application to add an additional manufacturer. The additional manufacturer will supply studies conducted under the Company's... has amended its Investigational New…
Alvotech and Advanz Pharma Submit European Application for AVT29, High-Dose Biosimilar to Eylea 8 mg
Alvotech and Advanz Pharma submitted AVT29 as a proposed biosimilar to Eylea® 8 mg for retinal disease treatment in Europe. AVT29 is a proposed biosimilar to Eylea® 8 mg (aflibercept), aimed at treating retinal diseases. The high-dose…
Alvotech and Lotte Biologics Enter into Strategic Partnership for Biosimilars
Home / News / BioBlast® On 6 October 2026, Alvotech announced that it has entered into a strategic manufacturing partnership for biosimilars with Lotte Biologics. a contract development and manufacturing organisation (CDMO) that provides…
LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity
BioPharma APAC - LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity 13 October 2026 | Tuesday | News LOTTE Biologics and Alvotech Partnership Signing Ceremony Collaboration covers…
Avalon Pharma Wins 15-year Exclusive Biosimilar License Deal in Saudi Arabia
Middle East Pharmaceutical Industries Co. , d/b/a Avalon Pharma, entered into a 15-year exclusive license contract with biopharmaceutical company Bio-Thera Solutions. The renewable agreement will... Middle East Pharmaceutical Industries…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com7
-
stocktitan.net5
-
manilatimes.net4
-
biopharminternational.com3
-
quiverquant.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 47 articles, not a forecast.